

## Vaccine Adjuvant Compendium

### ALT3

**Product Sheet** 

Last Updated: 04/06/2021 11:40 AM (EDT)
Author: Darrick Carter



#### **POC** and Institution

POC Name POC Title POC Email

Darrick Carter Head of Operations darrick.carter@pailifesciences.com

POC Institution Holds Intellectual Property Vaccine Ontology Identifier

PAI Life Sciences Yes



#### **Initial Details**

Adjuvant Name Chemical Nature Primary Receptor Secondary Receptor

Alt3 • Combination adjuvant- • TLR • TLR3

Alhydrogel with TLR3 agonist

Mechanism of Action Immune Profile Induced Drug Master File NIAID Support Other Features/Characteristics

TLR3 agonist plus potential Mixed Th1/Th2 No Yes

inflammasome

Stability Information Storage Information

At least 3 months at 2-8 degrees C 2-8 degrees C



### In Vivo Use (Preclinical)

Is there an associated PubMedID Disease Area/Pathogen Parent Organism

publication? Bacteria Mycobacterium tuberculosis

No

(serology)

•

Antigen Immunization Route Readout Host Species

Recombinant protein IM • Immunogenicity Mouse-C57BL/6

Were PK/Toxicology studies conducted?

No



# Product Grade and Formulation(s)

Product Grade

Research-grade only

Formulation(s)

Bedside mixing with antigen possible?

Yes

Also used in combination adjuvant-formulation?

lo



Clinical

Not evaluated in humans yet



**Additional Comments**